A Phase II Dose Titration Study of Thalidomide for Cancer-Associated Anorexia  by Davis, Mellar et al.
78 Journal of Pain and Symptom Management Vol. 43 No. 1 January 2012Original ArticleA Phase II Dose Titration Study of Thalidomide
for Cancer-Associated Anorexia
Mellar Davis, MD, Wael Lasheen, MD, Declan Walsh, MSc, FACP, FRCP (Edin),
Fade Mahmoud, MD, Leslie Bicanovsky, DO, and Ruth Lagman, MD
The Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Taussig Cancer Institute,
Cleveland, Ohio, USAAbstract
Context. Sixty-five percent of people with advanced cancer suffers from loss of
appetite. Several inflammatory cytokines appear to cause appetite loss in animal
models. Thalidomide is an immunomodulatory drug that has been associated with
improved appetite in those with HIV infections and cancer.
Objectives. We completed a two-stage Phase II dose titration study of
thalidomide, the primary purpose of which was to assess appetite response to
thalidomide in cancer-associated anorexia.
Methods. Individuals older than 18 years of age with active cancer, loss of
appetite by numerical rating scale (NRS), life expectancy of at least four weeks,
and Eastern Cooperative Oncology Group performance status of 0e3 were
entered into the study. Pretreatment screening included medical history,
neurologic examination, and symptoms by NRS and categorical scale (CAT).
Patients received 50 mg of thalidomide by mouth at bedtime for two weeks.
Individuals who did not respond were dose escalated to 100 mg at night for two
weeks. Assessment of appetite, early satiety, fatigue, insomnia, night sweats, pain,
and quality of life (QOL) occurred at two-week intervals. Toxicity also was
assessed. The primary outcome was appetite response defined as a two-point
reduction in the NRS or a one-point improvement in the CAT.
Results. Thirty-five patients entered the study; 33 completed 14 days of therapy
and were analyzed for efficacy and toxicity. Sixty-four percent who completed at
least two weeks of thalidomide had improved appetite. The CAT scores for
appetite, insomnia, and QOL improved significantly. The 95% confidence
intervals did not overlap. Five participants dropped out because of toxicity: two
before two weeks and three later.
Conclusion. Thalidomide reduced multiple symptoms commonly associated
with cancer-related anorexia and improved QOL. Our findings confirmed andThe Harry R. Horvitz Center for Palliative Medicine
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demonstrated greater benefits when thalidomide is used combined with other
agents to treat cancer-associated anorexia and cachexia. Thalidomide helped
cancer-associated anorexia in most patients. It also improved insomnia and QOL
in advanced cancer. J Pain Symptom Manage 2012;43:78e86.  2012 U.S. Cancer
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Sixty-five percent of advanced cancer pa-
tients suffers from anorexia, and over half
will have unintended weight loss greater than
10% of their premorbid body weight.1 Most
who report anorexia will have concurrent gas-
trointestinal (GI) symptoms, such as bloating,
constipation, diurnal changes in food intake,
early satiety, and an altered sense of smell
and taste.2 The presence of anorexia and sig-
nificant involuntary weight loss portends
a short survival and high symptom burden.3
Anorexia is part of a symptom cluster along
with weakness, fatigue, and lack of energy.
Treatment of one symptom within this cluster
might also ameliorate other cluster symp-
toms.4 Effective management of appetite and
weight loss should reduce symptom burden
and perhaps favorably influence survival.
The development of a validated instrument
to accurately measure anorexia is important
to research and clinical management. We re-
cently validated a two-item instrument that
measured appetite on a numerical rating scale
(NRS) (0 is complete loss of appetite, and 10 is
normal appetite) and patient-perceived sever-
ity by a categorical scale (CAT).5 This simpli-
fied questionnaire had a high concurrent
and predictive validity when compared with
the validated Functional Assessment of
Anorexia and Cachexia Therapy shortened
12 Question Version.5 It had moderate sensitiv-
ity to changes in appetite over seven days when
compared with the validated scale.
Mechanisms of appetite loss and unin-
tended weight loss are protean. Several inflam-
matory cytokines appear to cause anorexia and
cachexia in animal models.6 Serum levels of
Interleukin (IL)-1 and -6, tumor necrosis fac-
tor (TNF) alpha, vascular endothelial growthfactor (VEGF)-A, and VEGF-C are elevated in
cancer and associated with weight loss.7 Sys-
temic inflammation-based prognostic scales,
such as the Glasgow Prognostic Score (GPS),
predict nutritional decline and prognosis inde-
pendent of cancer stage.8 This provides a well-
defined therapeutic target for clinical trials.8
Thalidomide is an immunomodulatory drug
that inhibits VEGF and TNF alpha.9 It was orig-
inally licensed for erythema nodosum lepro-
sum in 1997. However, studies have shown
that thalidomide reduces wasting associated
with HIV infections.9 Significant weight gain
was seen with thalidomide 100 mg daily when
administered to those with wasting from HIV
infection. However, over half of the partici-
pants discontinued because of adverse events,
including somnolence, rash, neutropenia,
neuropathy, and dizziness.9 In another small
randomized trial of 28 individuals with HIV-
associated wasting, weight gain was greater on
low thalidomide doses compared with placebo;
the Karnofsky Index also improved relative to
placebo.10 Somnolence and rash were more
common with thalidomide. Response was
seen in 63% (22 of 35) of evaluable patients
with cancer-associated cachexia. Insomnia,
nausea, and well-being also improved.11 Re-
ported toxicity was mainly drowsiness and
dizziness.
We completed a thalidomide dose titration
study. The primary purpose was to assess the
appetite response to thalidomide in cancer-
associated anorexia. We also evaluated safety.
Secondarily, we wanted to determine if weight
gain occurred with thalidomide and if thalido-
mide influenced performance score measured
by the Eastern Cooperative Oncology Group
performance score (ECOG-PS). Changes in
lean body mass (LBM) measured by bioelectric
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nia, pain, and quality of life (QOL) were sec-
ondary outcomes.Methods
Twenty individuals (minimum) and 32 indi-
viduals (maximum) with advanced cancer
were to be enrolled in this dose titration study.
Patients were recruited from referrals to the
Palliative Medicine Service and from the De-
partment of Solid Tumor Oncology within
the Cleveland Clinic Taussig Cancer Institute.
Inclusion criteria were age greater than 18
years, active cancer, anorexia by NRS (0 no ap-
petite and 10 normal appetite), life expectancy
of at least four weeks, ECOG-PS of 0e3, and
ability to understand and communicate in En-
glish. This was an institutional review board-
approved study. Patients had to be willing
and able to comply with the Food and Drug
Administration-mandated System for Thalido-
mide Education and Prescribing Safety
(S.T.E.P.S.) program before study entry. Fe-
males of childbearing potential who refused
to use two methods of birth control (to start
four weeks before thalidomide) were ex-
cluded. Male patients with female partners of
childbearing potential were excluded if they
refused to wear latex condoms during sexual
encounters. Other exclusion criteria were the
following: peripheral neuropathy greater
than two as published by Feldman and
Stevens,12 concurrent chemotherapy or radia-
tion, hematologic malignancies, those unable
to take oral medications and food or those re-
quiring tube feedings or parenteral nutrition,
and use of appetite stimulants, such as cortico-
steroids, dronabinol, growth hormone, meges-
trol acetate, oxandrolone, or pentoxifylline.
Those individuals who, in the investigator’s
opinion, were at unacceptable risk if they par-
ticipated also were excluded.
Study treatment consisted of thalidomide
50 mg administered by mouth at bedtime for
two weeks. Those who responded were main-
tained on thalidomide for six weeks at the
investigator’s discretion and patient’s wish
to continue therapy. Individuals who did
not respond to 50 mg and were without
dose-limiting toxicity were dose escalated to
100 mg at night for two weeks; response wasthen reassessed. Patients who had not re-
sponded to 100 mg and did not have dose-
limiting toxicity could be dose escalated to
200 mg at bedtime. Those who experienced se-
vere or serious adverse events were withdrawn
from the study. Adverse events that could
lead to discontinuation were the following: un-
acceptable sedation and drowsiness as judged
by the patient or the physician, peripheral neu-
ropathy, development of an exfoliative, purpu-
ric, or bullous rash, fever >38C documented
on clinical measurements separated by
24 hours, or seizures. Other side effects, which
also were monitored by CAT (0 absent, 1 mild,
2 moderate, and 3 severe), included constipa-
tion, confusion, pruritus, pain, and swelling
in the limbs or face. Treatment was discontin-
ued if side effects were deemed severe or seri-
ous by the treating physician.
Thalidomide was obtained fromCelgene Phar-
maceuticals (Destin, Florida) after patients en-
rolled in the S.T.E.P.S. program. Thalidomide
50 mg capsules contained microcrystalline
celluloseNational Formulary (NF) (60 mg), povi-
done 90 F USP (12 mg), stearic acid NF (4 mg),
colloidal silicon dioxide NF (0.8 mg), crospovi-
done NF (16 mg), and anhydrous lactose NF
(257.2 mg). Patients were instructed to take their
dose at bedtime.
Assessment of Response and Toxicity
Pretreatment screening included the follow-
ing: medical history, neurologic examination, ap-
petite by NRS (0¼ no appetite and 10¼ normal
appetite) and CAT (0¼ normal appetite, level
1¼ 75% of normal intake, level 2¼ 50% of nor-
mal intake, 3¼<50% of normal intake, and
4¼ not eating at all), strength by NRS (0¼ no
strength and 10¼ normal strength), pain by
NRS (0¼ no pain and 10¼ severe pain), insom-
nia by NRS (0¼ sleeping well and 10¼ not sleep-
ing at all), sweating by NRS (0¼ no sweating and
10¼ severe sweating), nausea by NRS (0¼ no
nausea and 10¼ severe nausea), tiredness by
CAT (0¼ no tiredness and 5¼ cannot take care
of myself), early satiety by CAT (0¼ normal sense
fullness aftermeals and3¼ always full), andQOL
by a single-item CAT (0¼ quality of life very bad
and4¼ very good). Toxicities were assessedusing
a CAT (absent¼ 0, mild¼ 1, moderate¼ 2, and
severe¼ 3), not the CommonTerminology Crite-
ria for Adverse Events (CTCAE), and included
pain, muscle cramps, confusion, constipation,
Table 1
Demographic Data (n¼ 33)
Patient Characteristics Mean (SD) Median (Range)
Age, yr 68 (13) 69 (43e87)
n %
Gender
Male 17 51
ECOG-PS
0 1 3
1 15 47
2 14 41
3 3 9
4 0 0
Diagnosis
Lung cancer 13 39
GI cancer 12 36
Breast cancer 2 6
Head and neck 2 6
Others 4 12
All numbers rounded to the nearest whole number.
Vol. 43 No. 1 January 2012 81Thalidomide for Cancer-Associated Anorexiadizziness, drowsiness, dry mouth, headache, loss
of interest in sex, nervousness, pain in the stom-
ach, dry skin or pruritus, and limb swelling. Per-
formance score was measured by the ECOG-PS
(higher score worse). Weight was measured in
kilograms, LBM by BIA, C-reactive protein
(CRP) by standard, not highly sensitive CRP.
Pregnancy tests were done according to the
S.T.E.P.S. protocol. Patients underwent a weekly
history and physical examination and were
assessed for response and toxicity by telephone
every 48 hours. After six weeks, individuals were
followed in the outpatient clinic every two weeks.
The primary outcome was appetite response
defined as a two-point increase in NRS without
severe or serious adverse events. Secondary
endpoints were score changes in performance
status (one point), pain (two points), insom-
nia (two points), nausea (two points), night
sweats (two points), fatigue (one point), early
satiety (one point), and QOL (one point).
Higher scores were worse for all except
QOL. Compliance monitoring was not
performed.
Statistical Considerations
Descriptive statistics summarized variables at
each time point of assessment. Categorical var-
iables were summarized as frequencies and
percentages. Analysis of efficacy was based on
those given at least two weeks of thalidomide.
Eligibility for assessment of toxicity was based
on receipt of a single dose of thalidomide.
Treatment success was established if 60% of
treated individuals had improved appetite.
Failure was a response rate of less than or
equal to 40%. Twenty patients were initially en-
tered into the study. If eight or less of these re-
sponded, the study was to be stopped. If nine
or more responded, an additional 12 would
be added. If 16 individuals or less responded
over the two-week trial period, the study would
be considered negative. The power for the pri-
mary outcome measure was 0.83, with a signifi-
cance level of 0.09.
Changes in symptom severity from baseline
were analyzed by the Wilcoxon W test. Com-
parison of responders with nonresponders
was made with the Mann-Whitney test. Vari-
ables were compared using the Wilcoxon W
test. Categorical variables were compared us-
ing either Fisher’s exact test or the McNemar
test. Confidence intervals (CIs) from thestandard error of the means were calculated
for all significant P-values. All statistical tests
were two-sided, and the significance level was
P< 0.05.Results
Thirty-five patients gave consent and were
enrolled in the study. Two individuals did not
complete two weeks of therapy and were ex-
cluded from analysis; 33 patients completed
at least 14 days of therapy and were evaluable
for both response and toxicity. Demographics
of the patient population are shown in
Table 1. On Day 14, 17 of 33 individuals had
improved appetite. Nine of the 16 nonre-
sponders were then titrated to 100 mg of tha-
lidomide; seven of these withdrew after two
weeks (four refused titration, and three had
severe side effects as described below). By
Day 21, four of the remaining nine individuals
had responded; five were nonresponders.
Sixty-four percent of individuals who com-
pleted at least two weeks of thalidomide had
improved appetite. Furthermore, early satiety,
insomnia, pain, and QOL improved signifi-
cantly (Table 2).
Side effects were negligible for most
(Table 3). The mean score of the 13 poten-
tial side effect symptoms monitored by CAT
did not increase significantly for the entire
group. Two individuals did drop out because
of side effects before completing 14 days of
Table 2
Mean Symptom Scores at Baseline and Days 14e21 (n¼ 33)
Symptom
Baseline Day 14 or 21
P-valueaMean (SD) (95% CI) Mean (SD) (95% CI)
Appetiteb (by NRS) 3.5 2.0 (2.8e4.2) 5.7 2.6 (4.8e6.5) <0.001
Appetitec (by CAT) 2.5 0.6 (2.3e2.7) 1.9 0.9 (1.6e2.2) <0.001
Other symptomsc
Sweating 0.1 0.3 NS 0.5 1.7 NS NS
Pain 1.7 2.5 (0.9e2.6) 0.7 1.5 (0.2e1.2) <0.05
Night sleep 2.5 3.0 (1.5e3.5) 0.7 1.5 (0.2e1.2) <0.01
Nausea 0.5 1.7 NS 0.6 1.6 NS NS
Tired 2.7 1.3 NS 2.7 1.4 NS NS
Early satiety 1.2 1.1 (0.8e1.6) 0.8 1.0 (0.5e1.1) <0.05
QOL
QOL (CAT) 1.2 0.7 (0.5e0.9) 1.7 0.7 (1.4e1.9) <0.01
NS¼ nonsignificant P-values (CI only calculated for significant P-values).
aWilcoxon W.
bHigher scores better.
cHigher scores worse.
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toxicity score. Three withdrew after 14 days
because of side effects: one from severe
constipation, another from severe constipa-
tion and pruritus, and one with severe dry
mouth.Discussion
Thalidomide has a wide spectrum of actions,
including anti-inflammatory, antiangiogenic,
and antiemetic activity, sedation, and immu-
nomodulation.13 The anti-inflammatory and
immunomodulatory effects are largely attribut-
able to downregulation of TNF alphamessenger
RNA.14Theanticachectic action is closely relatedTable 3
Side Effects Associated W
Side Effects Baselinea (n, mean [SD])
Peripheral neuropathy 4, 0.2 (0.5)
Drowsy 13, 0.5 (0.7)
Confusion 7, 0.3 (0.7)
Nervousness 8, 0.3 (0.7)
Loss of libido 6, 0.9 (1.3) (15 missing)
Headache 2, 0.1 (0.2)
Dry mouth 15, 1.3 (1.4)
Abdominal pain 5, 0.3 (0.7)
Constipation 11, 0.8 (1.2)
Itching 3, 0.3 (0.8)
Limb/face swelling 6, 0.3 (0.8)
Dizzy 7, 0.4 (0.8)
Skin rash 0
Fever 0
Edema 5, 0.3 (0.9)
aHigher mean scores worse.
bWilcoxon W.to modulation of TNF alpha.15 TNF alpha and
IL-1 upregulate the hypothalamic melanocortin
system, and downregulate neuropeptide Y,
causing anorexia.16,17 Downregulation of TNF
alpha would improve appetite in inflammatory
disorders, such as HIV infections and
cancer.18e20
We found that thalidomide improved appe-
tite, sleep, and QOL to a significant degree
and reduced early satiety and pain but less so
(demonstrated by overlapping CIs for outcome
measures means). Four other studies investi-
gated thalidomide to treat cancer anorexia
and/or cachexia (Table 4). Two were random-
ized controlled trials (RCTs), one of which was
double blind and compared thalidomide withith Thalidomide
Thalidomidea (n, mean [SD]) P-value
3, 0.1 (0.4) NS
5, 0.2 (0.6) <0.05b
4, 0.3 (0.7) NS
5, 0.2 (0.5) NS
1, 0.2 (0.7) (18 missing) ¼0.1
0, 0 (0) NS
16, 1.1 (1.3) NS
3, 0.2 (0.5) ¼0.08
13, 0.8 (1.1) NS
3, 0.3 (0.9) NS
6, 0.3 (0.6) NS
5, 0.3 (0.6) NS
1 NS
0 NS
6, 0.6 (1.3) NS
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blind, had a high dropout rate at the first assess-
ment (17 of 47 individuals). LBM as measured
by mid-arm circumference improved at two
weeks.21 Weight also improved. There was no
change in handgrip strength (a surrogate
marker for fatigue and/or muscle mass). In
the second trial, thalidomide was compared
with various anticachexins.22 This study demon-
strated no appetite benefit by visual analogue
scale.22 There was no improvement in LBM
(by BIA or dual-emission X-ray absorptiometry
[DXA] scans), fatigue, resting energy expendi-
tures (REEs), handgrip, or appetite over the
four months on thalidomide alone. IL-1 and
GPS scores improved with thalidomide.22
Global health scores did not improve in either
study.21,22 Side effects were negligible in
the second trial, whereas the first reported
neuropathy, skin rash, somnolence, improved
insomnia, and constipation in some.21
In three single-arm studies (to include our
study), 83 patients were treated.23,24 Doses
were 50e200 mg. A small study treated 11 indi-
viduals with esophageal cancer. Compared
with weight loss during a two-week, before
treatment run-in period, thalidomide reduced
the rate of weight loss after two weeks of
200 mg per day.23 LBM by DXA scan increased
with thalidomide. QOL by Karnofsky Index
also improved. Basal metabolic rate was re-
duced, but the differences in the means had
overlapping CIs. Mild sedation was experi-
enced by most but disappeared after two to
three days.23
In the larger single-arm study, 37 of 72 indi-
viduals who started the study were evaluable.11
Initial thalidomide doses were 100 mg a day,
and responses were assessed approximately
10 days after initiating therapy. A severity
NRS measured difficulty falling asleep, restless-
ness in the morning, insomnia, nausea, appe-
tite, and well-being as primary outcomes. A
30% NRS reduction was deemed as a response.
Demographic characteristics resembled our
study. Appetite response was identical. Further-
more, insomnia and well-being improved in
over 50% of treated individuals. Nausea im-
proved in 44%. Most chose to continue thalid-
omide after the 10-day study. Dizziness,
drowsiness, and dry throat led to discontinua-
tion in five individuals. Most adverse effects
were mild.11Two studies of similar design (which includes
our own) demonstrated improved appetite with
thalidomide.11 Our experience validates the
earlier study. The fact that the percentage re-
sponse was the same and that the statistical sig-
nificance occurred without overlapping CIs by
CATmeasures (as in our study) provides confir-
matory evidence that thalidomide improves ap-
petite in cancer. Contrary to the two single-arm
studies, the large randomized trial did not find
appetite improvement when thalidomide was
added to a specialized polyphenol diet.22 Appe-
tite was a secondary endpoint, and comparisons
were made 16 weeks after starting thalidomide.
Appetite did improve when an omega-3 fatty
acid-rich supplement, L-carnitine, and proges-
terone were added to thalidomide. It may be
that the appetite benefits with thalidomide
were lost over time, the specialized polyphenol
diet (plus vitamins) may have stimulated appe-
tite similar to thalidomide, or there are additive
appetite benefits with combinations of agents.
Insomnia improved in both studies that used
it as an outcome. Improved insomnia with tha-
lidomide was reported over 40 years ago24,25
but not in cancer until recently. Insomnia is
one of the major symptoms in advanced can-
cer,26 so a medication that improves appetite
but also reduces insomnia is valuable.
The reported LBM improvement with thalid-
omide is controversial. The larger randomized
trial (longer follow-up than the smaller studies)
did not demonstrate improved LBM.22 In the
smaller randomized trial that used anthropo-
metric measurements, LBM was stable to im-
proved on thalidomide at four and eight
weeks, better than placebo.21 This study had
a high dropout rate, an imprecise LBMmethod,
and some sample andmeasurement biases. The
other single-arm study demonstrated some
LBMimprovementbyDXAscansbuthada small
sample size.23 Treatment time was two weeks.
Sample bias is likely. Even if individuals are
healthy and undergo resistance training to
increase muscle mass, size and fiber cross-
sectional areas do not increase for eight weeks.8
It would be difficult to see improved muscle
mass and LBM in such a short time in advanced
cancer. Therefore, it is likely that the improved
LBM in these two small trials reflected bias or
sample variability and selection and imprecise
measurement. Thalidomide may prevent or
forestall LBM loss; therefore, confirmatory
Table 4
Comparison of Thalidomide Studies
Study No. of Subjects Design Dose Outcomes Attrition Results Toxicity
Mantovani et al.22 332 (87 on
thalidomide alone,
88 on combination
with thalidomide)
RCT, not double blind
4-month duration
200 mg/d LBM, REE, appetite,
handgrip, QOL,
BIA, LBM, IL-6,
TNF-a, GPS, fatigue
3/87 (single
thalidomide arm
of the trial)
YECOG-PS
YIL-6
YGPS
No improvement in
appetite, fatigue,
LBM, REE,
handgrip
Negligible
Khan et al.23 11 Single arm
GI cancers
Two weeks
200 mg LBM, REE, Karnofsky
Index
1/10 [Body Weight
[LBM
[QOL
No improvement in
REE
N/A
Gordon et al.21 47 RCT/double blind
Pancreatic cancer
Four weeks
200 mg Weight Δ, mid-upper
arm circumference
handgrip, survival,
global health score
17/47 at four weeks,
27/47 at eight
weeks
[Weight gain and
maintained LBM.
No change in
handgrip, global
health score,
survival
Neuropathy
Rash
Somnolence
Constipation
YInsomnia
Bruera et al.11 37 Single arm
10 days
100 mg Difficulty falling
asleep, restlessness
in the morning,
insomnia, nausea,
appetite, well-being
35/72 [Insomnia
[Appetite
YNausea
[Well-being
Dizziness
Drowsiness
Dry mouth
Lightheadedness
Davis et al. (present
study)
33 Single arm
All cancers
Two weeks
50/100 mg Appetite, weight loss,
nausea, night
sweats, fatigue, early
satiety, pain,
insomnia
2/35 (14 days) [Appetite
YInsomnia
YEarly satiety
YPain
[QOL
No improvement in
weight, ECOG-PS,
nausea, fatigue
Negligible by CAT
8
4
V
ol.
4
3
N
o.
1
Jan
u
ary
2
0
1
2
D
avis
et
al.
Vol. 43 No. 1 January 2012 85Thalidomide for Cancer-Associated Anorexiaevidence is needed to prove that it improves
with thalidomide.
Neither fatigue nor handgrip improved with
thalidomide. Two studies demonstrated im-
proved well-being and QOL and one did not.
QOL instruments differed, and influences on
QOL may reflect different domains measured.
This requires further investigation.
Side effects with thalidomide were mild,
occurred in a minority in all studies and led to
drug discontinuation in a few individuals. This
maybe inpartdose-dependentbecause thehigh-
est dose was 200 mg. However, the analysis of
most studies was based on the treatment given
andnot intention to treat.The large randomized
trial had the longest treatment and fewdropouts;
toxicity was negligible. Hence, most individuals
tolerated thalidomide. The most common com-
plaints were sedation, drowsiness, and dizziness.
Rash, constipation, and neuropathy were rare.
Most studies were less than four weeks in dura-
tion, which may have played a role in the
reported side effect profile. This may be particu-
larly important with neuropathy (which usually
requires several months to develop).
The GPS improved with thalidomide in the
largest RCTs.22 IL-1 also was reduced with tha-
lidomide.22 The GPS is based on CRP and se-
rum albumin. Appetite may not improve with
thalidomide despite reduction in systemic in-
flammatory markers.8,22 Other thalidomide
mechanisms for appetite modulation need to
be considered.
There were weaknesses in our study. Second-
ary outcomes involvedCRPandBIA, whichwere
not completed. A nonvalidated CAT was used
for toxicity rather than the CTCAE. It was be-
lieved that the CTCAE would be inadequate to
assess thalidomide toxicity. Pain and early sati-
ety improved significantly (P-values), but CIs
overlapped, weakening the conclusion that im-
provements were from thalidomide. It was not
possible to separate placebo fromadrugbenefit
in this single-arm, open-label study. A placebo
effect is known to be significant for pain; this
also is likely true for anorexia. Changes in the
mean symptom score (even if significant) can
indicate either a large response in a few individ-
uals or little response in most. The percentage
of those in our study who had a two-point
change by NRS indicates that most benefited.
Individuals in our study were on multiple other
medications, including opioids; pain couldhave improved as a result of analgesic titration,
independent of thalidomide response. The
same could be true for QOL. This nonconsecu-
tive sample was small andmay not represent the
population of patients in our practice, although
age, gender, and distribution of cancer sites
of those on study resembled our usual patient
population. We excluded hematologic malig-
nancies because thalidomide is frontline
treatment for multiple myeloma.27 Symptom
improvement in lymphoplasmacytoid disorders
could be from tumor response rather than ap-
petite stimulation. Toxicity was low, but this
may have been a result of the short treatment
time and low thalidomide dose. These findings
are hypothesis generating. Insomnia, early sati-
ety, pain, and QOL were secondary outcomes.
The study was not powered for secondary out-
comes nor was it randomized.
Thalidomide should be investigated further
in randomized studies both as a single agent
and as a part of combination therapy. Novel
multiple endpoints should be considered for
these studies given thalidomide’s apparent
benefit in appetite, insomnia, and QOL. It
cannot be recommended for routine clinical
use based on our current information.
Conclusions
Thalidomide often improved appetite, in-
somnia, and QOL in advanced cancer. Toxicity
was, in general, low. The therapeutic dose for
symptom response is unknown: from our expe-
rience, responses occurred with low doses
(50e100 mg). Future randomized studies
should confirm these findings and explore var-
ious doses. Combination therapy (thalidomide
with L-carnitine, progesterone, and omega-3
fatty acids) may hold promise.22
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